Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...

Bone marrow biopsies are not a routinely recommended part of the work up and diagnosis of ITP in accordance to multiple international guidelines, but a new study re-examines this approach.

An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune ...

An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only manageable grade 1 to 2 toxicities and no cardiovascular or bleeding ...

Sanofi SNY announced that the FDA has approved Wayrilz (rilzabrutinib), a novel BTK inhibitor, for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adult patients who have had ...

— NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — The NMPA granted ...

Researchers have used various definitions to estimate the incidence and prevalence of immune thrombocytopenia (ITP) yet haven’t corroborated available data with large, population-based, multinational ...

Sanofi’s oral reversible Bruton’s tyrosine kinase (BTK) inhibitor, Wayrilz (rilzabrutinib), has secured approval from the US Food and Drug Administration (FDA) for adult patients with persistent or ...

Please provide your email address to receive an email when new articles are posted on . Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune ...

Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA ...